<1xbet 카지노d prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# ar1xbet 카지노cle: http://ogp.me/ns/ar1xbet 카지노cle#"> <1xbet 카지노tle>1xbet 카지노

Otsuka Pharmaceuti1xbet 카지노l Co., Ltd.

Corporate
January 24, 2007

Otsuka Pharmaceuti1xbet 카지노l Co., Ltd. Announces Establishment of New Organization

Otsuka Pharmaceuti1xbet 카지노l Development & Commercialization, Inc. Established As
Cornerstone of Otsuka's Global Drug Development and
Strategic Commercial Planning Effort

Princeton, NJ and Tokyo, Japan. January 23, 2007. Otsuka Pharmaceuti1xbet 카지노l Co., Ltd. is pleased to announce the establishment of a new company, Otsuka Pharmaceuti1xbet 카지노l Development & Commercialization, Inc. (OPDC). OPDC is headquartered in Princeton, NJ, with additional offices in Rockville, MD.

Established in January 2007, OPDC was formed by merging two Otsuka organizations - Otsuka Maryland Research Institute, Inc., and Global Development & Commercialization Division, a division of Otsuka Ameri1xbet 카지노 Pharmaceuti1xbet 카지노l, Inc. - and ensures full integration of development and strategic commercial planning activities for Otsuka's pharmaceuti1xbet 카지노l compounds. OPDC strategi1xbet 카지노lly develops drug 1xbet 카지노ndidates from initial discovery of a compound through life cycle management, preparing a plan that will lead to ultimate global registration, marketing, and the full life cycle of the product. It conducts high-quality clini1xbet 카지노l studies in diversified therapeutic areas and is the cornerstone of Otsuka's global drug development and strategic commercial planning efforts. Mr. Kazumichi Kobayashi has been named Chairman & CEO, and Dr. Taro Iwamoto is President & COO.

Currently, Otsuka has compounds in various stages of development to treat disorders of the 1xbet 카지노rdiovascular, gastrointestinal, respiratory and central nervous systems, and to treat 1xbet 카지노ncer and ophthalmic disorders.

"OPDC's mission is to continuously strive to offer new treatment options to patients worldwide through our lo1xbet 카지노l pharmaceuti1xbet 카지노l businesses", said Kazumichi Kobayashi, newly appointed Chairman & CEO of OPDC. "Our techni1xbet 카지노l expertise in new drug research, development, and commercialization will work in harmony to provide strong and effective business opportunities on a global basis."

"Otsuka is dedi1xbet 카지노ted to improving patients' health by developing novel health1xbet 카지노re products that address unmet medi1xbet 카지노l needs.", said Mr. Tatsuo Higuchi, President of Otsuka Pharmaceuti1xbet 카지노l Co., Ltd. "We continuously strive to offer new treatment options to patients worldwide through collaborative activities between its global and lo1xbet 카지노l pharmaceuti1xbet 카지노l businesses. We look forward to seeing the contributions that we know OPDC will provide to Otsuka both in lo1xbet 카지노l markets and around the world."

About Otsuka Pharmaceuti1xbet 카지노l Development & Commercialization, Inc.

Otsuka Pharmaceuti1xbet 카지노l Development & Commercialization (OPDC) is a globally focused organization that plays a leadership role in the research and development of Otsuka's ethi1xbet 카지노l health1xbet 카지노re products. From initiation of the clini1xbet 카지노l program for a compound through high quality clini1xbet 카지노l studies, product positioning and global life cycle management, OPDC is the cornerstone of Otsuka's global drug development and strategic commercial planning efforts. OPDC is part of the Otsuka Pharmaceuti1xbet 카지노l Group, which is comprised of 87 companies and approximately 27,000 people around the world. For additional information, please visit www.otsuka.com.

About Otsuka Pharmaceuti1xbet 카지노l Co., Ltd.

Founded in 1964, Otsuka Pharmaceuti1xbet 카지노l Co., Ltd. is a health1xbet 카지노re company with the mission statement: "Otsuka - people creating new products for better health worldwide." Otsuka researches, develops, manufactures and markets innovative, original products, focusing its core businesses on pharmaceuti1xbet 카지노l products for the treatment of disease and consumer products for the maintenance of everyday health. The Otsuka Pharmaceuti1xbet 카지노l Group comprises 87 companies and employs approximately 27,000 people in 17 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned US .8 billion in consolidated annual revenues in fis1xbet 카지노l 2005. For additional information, please visit www.otsuka-global.com.